PKO Investment Management Joint Stock Co Reduces Holdings in Amgen Inc. $AMGN

PKO Investment Management Joint Stock Co reduced its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 36.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 24,500 shares of the medical research company’s stock after selling 14,160 shares during the period. PKO Investment Management Joint Stock Co’s holdings in Amgen were worth $8,019,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of AMGN. Board of the Pension Protection Fund purchased a new position in Amgen during the fourth quarter worth $26,000. Olistico Wealth LLC purchased a new stake in shares of Amgen in the fourth quarter valued at $33,000. Cloud Capital Management LLC acquired a new stake in shares of Amgen during the third quarter valued at $34,000. Ares Financial Consulting LLC acquired a new stake in shares of Amgen during the fourth quarter valued at $34,000. Finally, Saranac Partners Ltd purchased a new stake in Amgen during the 3rd quarter worth about $37,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Q1 results beat expectations — AMGN reported $5.15 EPS vs. $4.73 consensus and product sales rose ~4%, with 16 drugs delivering double‑digit growth, supporting the company’s growth story. Amgen’s Q1 Earnings Top Estimates
• Positive Sentiment: Bullish analyst action — Goldman Sachs reiterated a Buy and lifted its price target to $425, signaling long‑term upside from execution and pipeline momentum. Goldman Sachs Raises PT to $425
• Positive Sentiment: Other supportive analyst notes — Some firms (e.g., William Blair) reiterated Buy ratings after the quarter, highlighting confidence in the MariTide/weight‑loss program and execution. Analyst Reiterates Buy
• Neutral Sentiment: Guidance set but roughly in line — Amgen updated FY‑2026 EPS guidance to $21.70–$23.10 (consensus ~22.29), which many read as broadly in‑line rather than materially bullish. Amgen FY2026 Guidance (press release/slide)
• Neutral Sentiment: Small, mixed analyst target moves — Truist nudged its target to $327 with a Hold rating (minimal change), leaving some investors watching for clearer directional signals. Truist Raises PT to $327
• Negative Sentiment: FDA action risk — The FDA proposed withdrawing Tavneos approval after alleging clinical‑trial data issues, raising regulatory, compliance and reputational concerns that can pressure the stock. FDA Tavneos Proposal Coverage
• Negative Sentiment: Investor apprehension over strategy/timing — Some market commentary framed the quarter as “generally in‑line” and expressed concern about Amgen’s aggressive push into obesity (MariTide) and the near‑term profit impact, contributing to selling pressure. Investor Reaction to MariTide Expansion

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the stock. Wells Fargo & Company boosted their target price on shares of Amgen from $375.00 to $390.00 and gave the company an “equal weight” rating in a research note on Thursday, March 19th. Guggenheim lifted their price target on shares of Amgen from $347.00 to $351.00 and gave the stock a “neutral” rating in a report on Thursday, April 9th. Barclays initiated coverage on shares of Amgen in a research report on Friday, February 20th. They issued an “equal weight” rating and a $350.00 price objective for the company. Freedom Capital downgraded shares of Amgen from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 12th. Finally, Leerink Partners restated a “market perform” rating and set a $355.00 target price on shares of Amgen in a research report on Thursday, March 5th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, fourteen have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $357.54.

Amgen Stock Down 4.7%

Shares of NASDAQ:AMGN opened at $329.82 on Friday. The company has a current ratio of 1.14, a quick ratio of 0.90 and a debt-to-equity ratio of 5.78. The firm has a market cap of $178.00 billion, a price-to-earnings ratio of 22.95, a PEG ratio of 3.26 and a beta of 0.44. The stock’s 50-day moving average price is $358.07 and its two-hundred day moving average price is $340.79. Amgen Inc. has a 12-month low of $261.43 and a 12-month high of $391.29.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, topping the consensus estimate of $4.77 by $0.38. Amgen had a net margin of 20.96% and a return on equity of 139.90%. The business had revenue of $8.62 billion for the quarter, compared to analyst estimates of $8.58 billion. During the same period in the prior year, the firm posted $4.90 EPS. The company’s revenue was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, research analysts forecast that Amgen Inc. will post 22.28 EPS for the current year.

Amgen Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be paid a dividend of $2.52 per share. The ex-dividend date of this dividend is Friday, May 15th. This represents a $10.08 dividend on an annualized basis and a yield of 3.1%. Amgen’s dividend payout ratio (DPR) is currently 70.84%.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.